Investigating brain changes and risks from new Alzheimer's treatments
Blood-brain barrier and microstructural brain biomarkers of ARIA and treatment outcomes with anti-amyloid immunotherapy for Alzheimer's disease
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-11052353
This study is looking at how new treatments for Alzheimer's disease might affect the brain, especially any potential risks, so we can better understand how to keep patients safe while using these therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11052353 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how new anti-amyloid immunotherapies for Alzheimer's disease affect the brain, particularly looking at potential risks like amyloid-related imaging abnormalities (ARIA) and changes in brain structure. By examining the blood-brain barrier and microstructural brain biomarkers, the study aims to identify mechanisms that could predict and monitor these risks. The approach includes advanced imaging techniques to differentiate between harmless changes and harmful neurodegeneration, which is crucial for the safe use of these therapies in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those who may be at higher genetic risk due to factors like the APOE4 allele.
Not a fit: Patients with other forms of dementia or those not diagnosed with Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatment guidelines for Alzheimer's disease, improving patient outcomes.
How similar studies have performed: Other research has shown promise in understanding the effects of anti-amyloid therapies, but this specific investigation into the blood-brain barrier and ARIA is a novel approach.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: REAS, EMILIE T. — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: REAS, EMILIE T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia